RT Journal Article
SR Electronic
T1 Role of Gallium-68 DOTATOC PET-CT in Neuroendocrine Tumors with Unknown Primary Site
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 143
OP 143
VO 56
IS supplement 3
A1 Menda, Yusuf
A1 O'Dorisio, Thomas
A1 Graham, Michael
A1 Howe, James
A1 Dick, David
A1 Dillon, Joseph
A1 Schultz, Michael
A1 Watkins, Gordon
A1 Sunderland, John
A1 O'Dorisio, M Sue
YR 2015
UL http://jnm.snmjournals.org/content/56/supplement_3/143.abstract
AB 143 Objectives Previous studies suggest a survival advantage in patients (pts) with metastatic neuroendocrine tumor (NET), who undergo resection of the primary tumor. The goal of this study is to evaluate Ga-68 DOTATOC PET-CT in localization of the primary NET in pts presenting with metastases and unknown primary site.Methods A single center prospective study was performed to evaluate the safety and efficacy of Ga-68 DOTATOC PET-CT in pts with proven or suspected NET. Ga-68 DOTATOC was produced under a physician-sponsored investigational new drug (IND) approval using an automated 68Ge/68Ga generator coupled with a ModularLab PharmTracer fluid handling system (Eckert-Ziegler). PET-CT scans were obtained approximately 60 min after the IV administration of 148 MBq of Ga-68 DOTATOC with a low-dose non-contrast CT. Images were interpreted qualitatively with focal uptake above normal background considered positive for NET.Results 36 pts with metastatic NET and unknown primary tumor site were evaluated with Ga-68 DOTATOC PET-CT. No primary tumor was identified in 7 pts, who did not have DOTATOC avid metastases. In 29 pts with DOTATOC avid metastases, Ga-68 DOTATOC PET-CT suggested a primary tumor site in 19 pts. The primary site indicated by Ga-68 DOTATOC PET-CT was confirmed in 11 pts, by histology in 8 and by imaging in 3 pts. There were 3 false positives, either nontumoral or lymphadenopathy suggesting primary tumor. 5 lesions identified on Ga-68 DOTATOC PET-CT scans remain unconfirmed. 7 pts underwent resection of primary tumor and 1 pt underwent peptide receptor radionuclide therapy, resulting in a major change in management in 28% of pts, who have DOTATOC avid metastases and unknown primary tumor site.Conclusions Ga-68 DOTATOC PET-CT can identify the primary tumor, which leads to a significant change in management in pts with metastatic NET and unknown primary tumor site.